Allan Harris
Long/short equity, newsletter provider, Dynamic Trend Following, Option Tradnig

Cellceutix And Kevetrin Aligning With The Pharmacyclics Growth Curve

On December 18, 2012, I published a Seeking Alpha article naming Cellceutix (OTCQB:CTIX) as my Stock of the Year for 2013. Six months into the year, let's take an updated look why CTIX is still my 2013 Stock of the Year.

The recent offer by Amgen (NASDAQ: AMGN) to buy Onyx Pharmaceuticals (NASDAQ: ONXX) is the latest in a string of acquisitions that has cancer drug makers on the hot list again. Effective oncology drugs can command a premium like no other, which is why I maintain an extremely bullish stance on Cellceutix as one of the most compelling biotechnology companies today and for the future. Shares have spiked to deliver gains as high as 150...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details